A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients

Annals of Allergy, Asthma and Immunology

Volumn 88, Issue 5, 2002, Pages 488-493

  Langley, Stephen J ^a   Sykes, Andrew P ^b   Batty, Elizabeth P ^a   Masterson, Catherine M ^a   Woodcock, Ashley ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUORINATED HYDROCARBON; NORFLURANE; SALBUTAMOL;

ADOLESCENT; ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MUSCLE CRAMP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TREMOR;

EID: 0036590850     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62387-3     Document Type: Article

References (22)

1. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes chlorine-atom catalysed destruction of ozone. Nature 1974;249:810-814.
2. UK Department of the Environment. The Ozone Layer. London: UK Department of the Environment; 1995. Reference 95EP053.
3. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000;94(Suppl): S3-S9.
4. Dolovich M. New delivery systems and propellants. Can Respir J 1999;6:290-295.
5. Levy ML. Metered dose inhalers: current and future issues. Br J Clin Pract Suppl 1997;89:16-21.
6. Kerem E, Levison H, Schuh S, et al. Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. J Pediatr 1993;123:313-317.
7. Lin YZ, Hsieh KH. Metered dose inhaler and nebulizer in acute asthma. Arch Dis Child 1995;72:214-218.
8. Bisgaard H. Delivery options for inhaled therapy in children under the age of 6 years. J Aerosol Med 1997;10(Suppl):S37-S40.
9. Lumry W, Noveck R, Weinstein S, et al. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. Ann Asthma Allergy Immunol 2001;86:297-303.
10. Grady J, Stahl E, Davis S, Liddle R. A comparison of albuterol MDI in CFC propellant (P11/12), albuterol MDI in non-CFC propellant (HFA 134a propellant alone) in asthmatic subjects. Am J Respir Crit Care Med 1996;153: A62.
11. Shapiro G, Bronsky E, Murray A, et al. Clinical comparability of ventolin formulated with hydroflouroalkane (HFA) or conventional chlorofluorocarbon (CFC) propellants in children with asthma. Arch Pediatrics Adolesc Med 2000;154:1219-1225.
12. Salat D, Popov D, Sykes AP. On behalf of an Eastern European Study Group. Equivalence of salbutamol 200 μg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Respir Med 2000;94(Suppl):S22-S28.
13. Taggart SC, Custovic A, Richards DH, Woodcock A. GR106642X: a new, non-ozone depleting propellant for inhalers. BMJ 1995;310:1639-1640.
14. Custovic A, Taggart SC, Stuart A, et al. Efficacy of a new non-ozone depleting formulation for salbutamol. J Pharm Med 1995;5:161-168.
15. Dockhorn RJ, Wagner DE, Burgess GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to Proventil and Ventolin. Ann Allergy Asthma Immunol 1997;79:85-88.
16. Colice GL, Klinger NM, Ekholm BP, Dockhorn RJ. Proventil HFA prevents exercise-induced bronchoconstriction in children. J Asthma 1999;36:671-676.
17. Ramsdell J, Ekholm BP, Klinger NM, Colice GL. Safety of long-term treatment with HFA albuterol. Chest 1999;115:945-951.
18. Craig-McFeely PM, Soriano JB, Dunn NR, et al. Prospective observational cohort safety study to monitor in the introduction of a non-CFC formulation of salbutamol with HFA 134a in the UK. Eur Respir J 2000;16:99S.
19. Grady J, Stahl E, Davis S, Liddle R. A placebo-controlled study of the cardiac safety of salbutamol in CFC propellant (P11/12) and salbutamol in non-CFC propellant (HFA 134a). Eur Resp J 1996;9(Suppl):51S.
20. Bornkessel B. A new CFC-free salbutamol MDI: results of a survey of Sultanol N-experience from the doctor's office. Deutsche Apothekerzeit 1998;138:S1-S4.
21. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346-1353.
22. Woodcock A, Custovic A, Smith A. Metered dose inhalers: the need for change. Eur Respir Rev 1998;8:179-180.